Stocks Down Under Videos

Get a 3-month FREE TRIAL to CONCIERGE now!

Concierge gives you timely BUY and SELL alerts on ASX-listed stocks

Test Concierge Now!

Imagion Biosystems (ASX:IBX) is getting ready for a Phase 2 study: Interview with Chair Bob Proulx

August 11, 2025

IBX, Imagion Biosystems

Imagion Biosystems (ASX:IBX)

We talked with Bob Proulx, Executive Chairman of Imagion Biosystems, about the company’s progress with MagSense. Imagion now has data on the clinical utility of MagSense in detecting metastases in Her-2 positive breast cancer. The company is now recapitalised and getting ready for a Phase 2 study.

Check out our research on Imagion Biosystems here!

 

Disclosure: Imagion Biosystems is a research client of Pitt Street Research and our directors own IBX shares.

 

Looking for the Best ASX Life Sciences stocks to invest in right now?

 

 

View All